Salvage Surgery for Primary Renal Pelvic Urothelial Carcinoma After Enfortumab Vedotin: A Case of Durable Remission With Nectin‐4 Loss
This case highlights the potential role of surgery for localized progression during enfortumab vedotin therapy. Nectin-4 reassessment may be considered selectively at decision-changing junctures when results are likely to alter management.
Authors
- Satoshi Muraoka
- Hiroki Kawabata
- Takahito Wakamiya (ORCID: https://orcid.org/0000-0001-9101-1749)
- Yasuo Kohjimoto (ORCID: https://orcid.org/0000-0001-6103-6320)
- Shimpei Yamashita (ORCID: https://orcid.org/0000-0001-7402-6164)
- Yuya Iwahashi (ORCID: https://orcid.org/0000-0002-4201-1985)
- Fumiyoshi Kojima (ORCID: https://orcid.org/0000-0002-9478-9692)
Institutions
- Wakayama Medical University (JP)
Publication Details
- Journal
- IJU Case Reports
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1002/iju5.70122
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wakayama Medical University